Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.
Vigabatrin (VGB) is an important treatment option for infantile spasms. Vigabatrin-induced visual field defects are at present the most important safety issue in the use of the drug. The knowledge concerning VGB-associated visual dysfunction in pediatric patients, particularly in those who have been exposed to VGB in utero is limited. We explored ophthalmic and neurologic findings in two children who have been exposed prenatally to VGB.
Sorri
Iiris
I
Department of Ophthalmology, Kuopio University Hospital, P.O. Box 1777, FIN-70211 Kupio, Finland. iiris.sorri@uku.fi
Herrgård
Eila
E
Viinikainen
Katriina
K
Pääkkönen
Ari
A
Heinonen
Seppo
S
Kälviäinen
Reetta
R
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects*; D002648:Child; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D007839:Functional Laterality; D006801:Humans; D008297:Male; D009460:Neurologic Examination / Q000379:methods; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011930:Reaction Time / Q000187:drug effects; D014599:Uterus / Q000187:drug effects; D020888:Vigabatrin / Q000009:adverse effects*; D014786:Vision Disorders / Q000209:etiology*; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
D000927:Anticonvulsants; D020888:Vigabatrin